Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1086 | 1138 | 1198 | 1156 | 1723 | 2531 |
Fund Return | 8.57% | 13.76% | 19.82% | 4.94% | 11.5% | 9.73% |
Place in category | 834 | 861 | 1174 | 874 | 937 | 755 |
% in Category | 66 | 68 | 98 | 79 | 89 | 92 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Aberdeen Emerging Markets Instl | 616.37M | 7.24 | -7.15 | 2.19 | ||
Aberdeen Emerging Markets Instl Svc | 436M | 7.05 | -7.30 | 2.04 | ||
Aberdeen US Small Cap Equity Inst | 213.77M | -1.81 | 1.80 | 9.33 | ||
Aberdeen US Multi-Cap Equity Instl | 116.26M | 8.57 | 5.18 | 9.96 | ||
Aberdeen US Small Cap Equity A | 111.69M | -1.84 | 1.42 | 8.97 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
American Funds Growth Fund Amer A | 153.75B | 22.40 | 4.47 | 13.21 | ||
Fidelity Contrafund | 128.94B | 30.86 | 9.80 | 15.03 | ||
Fidelity Contrafund K | 128.94B | 30.89 | 9.88 | 15.12 | ||
Vanguard Growth Index Adm | 83.57B | 23.69 | 7.47 | 15.16 | ||
JPMorgan Large Cap Growth R6 | 66.51B | 26.92 | 9.12 | 17.38 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Microsoft | US5949181045 | 13.96 | 417.00 | +1.00% | |
Mastercard | US57636Q1040 | 5.87 | 520.86 | +1.12% | |
Merck&Co | US58933Y1055 | 4.64 | 99.18 | -0.68% | |
Eli Lilly | US5324571083 | 4.38 | 748.01 | -0.25% | |
Integer Hld | US45826H1095 | 4.08 | 138.11 | +1.64% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy |
Summary | Strong Buy | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review